In short
Clinical trials are investigating Alclometasone Dipropionate as one treatment used in studies of atopic dermatitis. These trials aim to evaluate treatment effects and safety in people with moderate to severe disease, often compared with placebo and other skin treatments.
Key points
- Clinical trials involving Alclometasone Dipropionate in the provided data are focused on atopic dermatitis, also called eczema. The study is a Phase 2 interventional trial and included people with moderate to severe disease. It compared several treatments, including placebo, ANB032, hydrocortisone, and Alclometasone Dipropionate. The main result being measured was the change in EASI score at Week 14. The trial planned to enroll 160 people, but its status is Withdrawn.
Trial overview
The provided trial is an interventional study, which means researchers assigned treatments to study participants instead of only observing them. It was designed to assess the clinical efficacy and safety of ANB032 in people with moderate to severe atopic dermatitis, and Alclometasone Dipropionate was one of the study treatments listed.
Who was studied
The target condition was atopic dermatitis, a long-lasting itchy skin disease also known as eczema. The study focused on subjects with moderate to severe disease, so it was not aimed at mild cases.
Treatments in the study
The study compared several treatments: placebo matching the investigational product, ANB032 given by subcutaneous injection, hydrocortisone for cutaneous use, and Alclometasone Dipropionate for cutaneous use. A placebo is a look-alike treatment that does not contain the active study drug, and cutaneous use means use on the skin.
Because Alclometasone Dipropionate was included among the study interventions, the trial data show it as part of a broader comparison of skin treatments in atopic dermatitis.
What was measured
The main endpoint was the mean change from baseline in Eczema Area and Severity Index (EASI) at Week 14. Baseline means the starting point before treatment, and EASI is a score used to measure how severe eczema is and how much skin is affected.
Trial status and size
The trial phase was Phase 2, which is a stage that usually looks more closely at whether a treatment may work and continues safety checking. The planned enrollment was 160 people, but the study status was Withdrawn, meaning it was stopped before completion.